Search

Introduction: The trunks barks of Anogeissus leiocarpus contains multiple antihypertensive components and are, therefore, widely used for the treatment of hypertension. Objective: This study aimed to formulate capsules containing a freeze-dried aqueous extract of the trunk’s barks. Methodology: Three (03) capsule formulations were prepared using wet granulation from lyophilised aqueous extract of Anogeissus leiocarpus trunk bark, with different proportions of excipients including Corn starch used as the diluent, Polyvinylpyrrolidone K25 (PVP) used as binding agent and Magnesium stearate used as gliding agents. The filling of capsules was done using a semi-automatic capsule filler with empty capsules of size 3. The flow properties of the granules and the quality control were performed according to the European Pharmacopoeia 10th ed. Results/Discussion: All granules had good flow properties, and the F1 and F3 formulations had the best pharmaceutics characteristics according to the recommendations of the European Pharmacopoeia 10th ed. The mean levels of phenolic tracers were 0.039±0.0097 mg gallic acid equivalent per capsule (GAE/capsule) for the F1 formulation and 0.059±0.0063 mg GAE/capsule for the F3 formulation. Conclusion: This study allowed the galenic formulation of capsules based on extracts of good characteristic quality for the treatment of hypertension. Keywords: Anogeissus leiocarpus, extract, excipients, formulations, capsule

Lazare Belemnaba,1 Mathieu Nitiéma,1 Sylvain Ilboudo,1 Gueswindé Geoffroy Ouédraogo,1 Noufou Ouédraogo,1 Mohamed Bonewendé Belemlilga,1 Souleymane Compaoré,1,2 Salfo Ouédraogo,1,2 Sylvin Ouédraogo1 1Institut de Recherche en Sciences de la Santé/Centre National de la Recherche Scientifique et Technologique (IRSS/CNRST), 03 BP 7047, Ouagadougou, 03, Burkina Faso; 2Université Joseph KI-ZERBO, 03 BP 7021, Ouagadougou, 03, Burkina FasoCorrespondence: Lazare BelemnabaResearch Institute for Health Sciences (IRSS), Department of Medicine and Traditional Pharmacopeia (MEPHATRA/Ph), National Centre for Scientific and Technological Research (CNRST), 03 BP 7047, Ouagadougou, 03, Burkina FasoTel +226 25 36 33 64/25 36 32 15Fax +226 25 36 28 38/25 36 03 94Email lbelemnaba2@gmail.comBackground: The present study investigates the effect of an aqueous extract of Anogeissus leiocarpa (AEAL) on normotensive Wistar rats and its chronic antihypertensive effects in L-NAME-induced hypertensive rats by using a non-invasive tail-cuff model.Methods: The effects of AEAL (50mg/kg) and NaCl 0.9% on blood pressure were investigated by daily oral administration in normotensive Wistar rats over four weeks. L-NAME-induced hypertensive rats were produced by L-NAME (40mg/kg) daily oral administration for two weeks. For chronic antihypertensive effects, induced hypertensive rats have received L-NAME in combination with AEAL (10 or 50mg/kg/day) for two following weeks.Results: In normotensive rats, daily administration of AEAL (50mg/kg) has no significant effect on their blood pressure, which was similar to that of the control group. L-NAME’s daily oral administration induces a progressive increase in systolic blood pressure (SBP) from 115.8 ± 7.9mmHg to 153.5 ± 4.6mmHg after two weeks, which was maintained to the end of the treatment. In L-NAME-induced hypertensive rats, AEAL (50mg/kg/day) significantly decreases the SPB from 160.0 ± 5.8 mmHg to 108.8 ± 2.7mmHg after only four days of administration. However, the lower dose of AEAL (10mg/kg) also normalized the SBP of L-NAME-induced hypertensive rats but only evident after seven days of administration. Moreover, AEAL does not effect on the serum biochemical parameters (ALAT, ASAT, CREAT, etc.) and any macroscopic adverse effect was detected on the sensible organs involved during hypertension. In the aorta rings from treated rats, AEAL (50mg/kg/day) alone or in combination with L-NAME has enhanced the vasodilation effect of acetylcholine. However, the vasodilation effect of AEAL alone or in association with L-NAME has enhanced the sodium nitroprusside effect in treated rat aorta rings after autopsy.Conclusion: These findings suggest that AEAL affords significant antihypertensive effects against L-NAME-induced hypertensive rats without modification of serum parameters and deleterious effects.Keywords: Anogeissus leiocarpa, non invasive, L-NAME-induced hypertension, vasorelaxation

Lannea microcarpa, is one of the species of medicinal plants used in medicine and traditional pharmacopoeia for the treatment of human pathologies in Africa. This review focuses on the ethnobotanical and ethnopharmacological previous studies of Lannea microcarpa. Some information on phytochemical makeup and its effects on human health are already documented. However, information concerning its ethnopharmaceutical and phytopharmaceutical potential is scarce and poorly documented. These data were obtained by documentary researches using different scientific sites such as Google Scholar, Science Direct, Scopus, ResearchGate, PubMed, and SCIENCEDOMAIN, from theses, dissertations and scientific articles. Additional information was obtained from classic books about herbal medicine and others scientific databases. Ethnobotanical surveys carried out have indicated their uses in the management of arterial hypertension. It appears from bibliographic research that Lannea microcarpa has vasorelaxant, hypotensive and antihypertensive effects, etc. Other studies have shown the presence of phytochemicals of interest for the management of high blood pressure. However, their use in traditional forms does not make it possible to guarantee the stability of medicinal preparations. Quality control and standardization studies were carried out in order to define the optimal conditions for guaranteeing effectiveness. This article gives an overview of previous studies carried out on the plant in order to have data for the improvement of its use.

Les plantes constituent un réservoir pour les pharmacopées du monde. Plusieurs médicaments importants sont fabriqués à partir des substances actives d’origine végétales. En outre de nombreux médicaments modernes ont été fabriqués à partir de ces matières premières. Les plantes médicinales sont utilisées directement sous forme fraîche, sèche ou transformée, stabilisée, ou extrait ou formulée avec d’autres plantes ou excipients de synthèse. Dans tous les cas, la matière végétale utilisée pour fabriquer la forme posologique doit faire preuve de son efficacité, son innocuité et être de qualité conforme aux exigences de la Pharmacopée Européenne pour les phytomédicaments, garantissant ainsi sa sécurité d’emploi. Pour ce faire, l’Organisation Mondiale de la Santé (OMS) a mis à la disposition des états membres des guides et standards permettant d’harmoniser et de sécuriser leur utilisation. Ainsi de nombreux pays africains ont adopté ces outils après des modifications appropriées pour faire progresser la recherche et le développement (R&D) de médicaments à base de plante. Le but de ce travail était de faire une synthèse des différentes étapes de production, de contrôle qualité et de standardisation des matières premières issues des plantes médicinales et des médicaments à base de plantes médicinales.Mots clés : Pharmacopée, médicaments, médecine traditionnelle, sécurité d’emploi, phytomédicaments. English title: Production of raw materials and manufacturing of drugs from medicinal plants Plants are a reservoir for the world's pharmacopoeias. Several important medicines are made from active substances of plant origin. In addition, many modern medicines have been made from these raw materials. Medicinal plants are used directly in fresh, dry or processed, stabilized, or extracted form or formulated with other plants or synthetic excipients. In all cases, the herbal material used to manufacture the dosage form must demonstrate its efficacy, safety and be of a quality that meets the requirements of the European Pharmacopoeia for phytomedicines, thus ensuring its safe use. To this end, the World Health Organization (WHO) has made available to Member States guides and standards to harmonize and secure their use. Thus, many African countries have adopted these tools after appropriate modifications to advance research and development (R&D) of plant-based drugs. The aim of this work was to make a synthesis of the different stages of production, quality control and standardization of raw materials from medicinal plants and herbal medicines.Keywords: Pharmacopoeia, drugs, traditional medicine, safe use, phytomedicines.

Aims: We aimed in this study to investigate the mechanisms of the vasorelaxation effect caused by the anthocyanins-enriched extract of Odontonema strictum flowers. Study Design: Anthocyanins-enriched extract of Odontonema strictum flowers and vasorelaxantes activities of mice aortic rings. Place and Duration of Study: The flowers of Odontonema strictum (Nees) Kuntze (Acanthaceae) were collected in January 2015 at the “Institut de Recherche en Sciences de la Santé (IRSS)” experimental station in Ouagadougou. The experiments were conducted in October - November 2018 at the department of Medicine and Traditional Pharmacopeia-Pharmacy (MEPHATRA-PH)/IRSS. Methodology: The extract was enriched in anthocyanins using Amberlite XAD-7 non-ionic resin column. The vasorelaxant activity of anthocyanins-enriched extract of O. strictum flowers (OSF) was tested using isolated organ-chamber technique with mice aorta rings. Results: OSF showed concentration-dependent relaxant effects on mice endothelium intact or denuded aortic rings pre-contracted with U46619 (10-7 M) and KCl (80 mM). OSF induced relaxation in the mice aortic rings by stimulating smooth muscle cells. The vasorelaxant effect of OSF (10-1000 µg/mL) was similar in endothelium-intact and endothelium-denuded aortic rings. The maximum relaxant effect was 93.78 ± 4.69% and 92.30 ± 3.19% for endothelium-intact and endothelium-denuded aortic rings, respectively. Moreover, after incubation of the aorta rings with OSF (400 µg/mL) or vehicle (0.02% of DMSO) in PSS, OSF blocked the contraction through mechanism involving inhibition of CaCl2 and U46619 effect. Conclusions: The present study provides a pharmacological evidence for the antihypertensive medicinal use of Odontonema strictum by highlighting its vasorelaxant activity.

Aims: This study investigated the antioxidant activity and the 90 days subchronic toxicity of the standardized LAMIC phytomedicine prototype based on aqueous extracts from Lannea microcarpa trunk bark. Methods: Three spectrophotometric methods were used to evaluated the antioxidant activity of LAMIC which were 2,2-Diphenyl-1-picrylhydrazyl (DPPH) free radical, 2,2’-azinobis(3-ethylbenzolin-6-sulphonate) (ABTS) radical scavenging assays and ferric reducing antioxidant power (FRAP) assays. For the standardized LAMIC subchronic toxicity study, male and female Wistar rats were used by daily oral administration at doses of 500, 1000 and 1500 mg/kg bw consecutively for 90 days. Results: The LAMIC extract exhibit better inhibitory activity against DPPH radical than ABTS radical with respective IC50 values of 45.38±3.21 µg/mL and 66.45±18.76 µg/mL, while FRAP assay exhibit antioxidant activity of 211.34±15.92 mmol EAA/g. Subchronic oral administration of LAMIC was well-tolerated at all tested doses. No behavioral and physiological changes and mortality were observed. The LAMIC extract did not present any impact on general hematological parameters and biochemical parameters. Moreover, no significant changes were raised in organ and body weight of treated groups compared to the Control group. Conclusion: These results support that LAMIC prototype was a valuable source of natural antioxidants and no toxicity was associated to its long terms oral consumption in rats indicating a potential application as a cardiovascular protective formulation. Keywords: LAMIC–Lannea microcarpa–Standardization–Antioxidant–Subchronic toxicity.

Background Acacia senegal is a plant traditionally used for its various properties, including the treatment of infectious diseases. Recently, our team has demonstrated the ability of the hydroethanolic extract of the leaves to increase the activity of phenicol antibiotics against multi-resistant bacteria. The aim of this work is to determine the toxicological effects of the extract and its capacity to inhibit the bacterial mobility of Gram-negative bacteria, in order to evaluate the level of safety use of this plant. Methods The cytotoxicity test was performed using the neutral red absorption method. Acute and sub-acute oral toxicity were conducted on NMRI mice and Wistar rats. The behaviour and adverse effects were recorded during the 14 days of the acute study. For the subacute test, biochemical parameters, food and water consumption, and morphological parameters were determined. The anti-motility activities were evaluated on Pseudomonas aeruginosa PA01 and Escherichia coli AG100, using specific concentrations of Agar as required by the method. Results HEASG induced inhibition of keratinocytes cell growth with an IC50 of 1302 ± 60 μg/mL. For the acute toxicity study in mice, the single dose of extract of 2000 mg/kg body weight caused no deaths and no behavioural changes were observed; therefore, the median lethal dose (LD50) of HEASG was calculated to 5000 mg/kg body weight. In Wistar rats, no mortality was observed at 250, 500 and 1000 mg/kg/day during the 28-day subacute oral toxicity study. The weights of both females and males increased globally over time, regardless of the batch. No statistically significant differences were registered for organ weights and biochemical parameters, except for chloride for biochemical parameters. Water and food consumption did not change significantly. Furthermore, no macroscopic changes in organ appearance were observed. Regarding anti-motility activity, the extract has reduced the swarming motility of PA01 and AG100 significantly at the concentration of 32 μg/mL (P P Conclusions The results suggest that hydroethanolic extract of A. senegal leaves has significant activity against bacterial motility and relatively low toxicity.

Waltheria indica L. (Malvaceae) is a plant used in Burkina Faso for the treatment of various ailments including asthma. The aim of the study was to evaluate the pharmacological relaxant effect of the leafy stem extracts of Waltheria indica and thereby verify claim of use in treating asthma. Aqueous decoction and hydroalcoholic extracts obtained from the powdered leafy stems were screened for the presence of some phytoconstituents. The in vitro relaxant effect of the two extracts was evaluated on acetylcholine- (ACh 10−5 M) and potassium chloride- (KCl 6 × 10−2 M) induced contractions on rat-isolated tracheal preparations. To examine whether the potassium (K+) channels are involved in the relaxant effect, glibenclamide, an ATP-sensitive potassium channel inhibitor, was used. Moreover, to assess the safety of the extracts, acute oral toxicity was carried out on mice. The phytochemical screening revealed the presence of alkaloids, flavonoids, saponins, steroids, triterpenoids, tannins, and coumarins in the hydroalcoholic extract. Tannins, steroids, triterpenoids, and coumarins were not detected in the aqueous decoction. With respective EC50 values of 1.517 ± 0.002 mg/mL and 1.433 ± 0.001 mg/mL on ACh-and KCl-provoked contractions, the hydroalcoholic extract was found more potent in relaxing the isolated rat tracheal preparations compared to the aqueous decoction. In the presence of glibenclamide, the relaxant effect of the hydroalcoholic extract (EC50 = 0.191 ± 0.002 mg/mL) increased and was higher than that of the aqueous decoction. At dose of 5000 mg/kg of body weight, the extracts did not produce deaths or any significant changes in the general behavior of mice. The results suggest that different mechanisms including modulation of calcium and potassium channels, particularly the ATP-sensitive K+ channels, could be involved in the relaxation effect. These findings could justify the traditional use of W. indica in the management of asthma.

Background:Anogeissus leiocarpusis a Sahel tree traditionally used by the residents of Burkina Faso for its antihypertensive properties. In this study, experiments were conducted to evaluate whether an aqueous extract of theAnogeissus leiocarpus(AEAL) trunk bark induces a vasorelaxant effect on porcine coronary artery rings and to investigate the underlying mechanism.Methods:AEAL-induced relaxations were assessed using porcine coronary artery rings suspended in organ chambers. The phosphorylation levels of Src, Akt and endothelial nitric oxide synthase (eNOS) were assessed in a primary endothelial cell culture by Western blot. The reactive oxygen species (ROS) formation was assessed using dihydroethidine.Results:In porcine coronary artery rings, AEAL at 0.1–300 μg/mL induced endothelium-dependent relaxations, which were inhibited in the presence of inhibitors of nitric oxide (NO) and the endothelium-derived hyperpolarization pathways. Moreover, the AEAL-induced NO-mediated relaxations were significantly reduced by the inhibitors of Src and PI3-kinase as well as by the membrane-permeant ROS scavengers. In cultured porcine coronary artery endothelial cells, treatment with AEAL is associated with an intracellular generation of ROS. Moreover, the AEAL induced the phosphorylations of Akt (Ser473), eNOS (Ser1177) and a transient phosphorylation of Src (Ser17) in a time-dependent manner.Conclusions:These findings indicate that AEAL is a potent inducer of endothelium-dependent NO-mediated relaxations in porcine coronary arteries through the redox-sensitive Src/PI3-kinase/Akt pathway-dependent activation of eNOS.

Background The present study investigates the effect of AEAL on normotensive Wistar rats and its chronic antihypertensive effects in L-NAME-induced hypertensive rats by using a non-invasive tail-cuff model. Methods The effects of AEAL (50 mg/kg) and NaCl 0.9% on blood pressure were investigated by daily oral administration in normotensive Wistar rats over four weeks. L-NAME-induced hypertensive rats were produced by L-NAME (40 mg/kg) daily oral administration for two weeks. For chronic antihypertensive effects, animals were treated with L-NAME for two weeks and then, L-NAME was administrated in combination with AEAL (10 or 50 mg/kg/day) and compared with a control group receiving only NaCl 0.9% for two following weeks. The blood pressure was measured daily by a Blood Pressure Recorder system. Results In normotensive rats, daily administration of AEAL (50 mg/kg) had no significant effect on their blood pressure, which was similar to that of the control group. Daily oral administration of L-NAME induced a progressive increase in systolic blood pressure (SBP) from 115.8 ± 7.9 mmHg to 153.5 ± 4.6 mmHg after two weeks of treatment, which was maintained to the end of the treatment. In L-NAME-induced hypertensive rats, AEAL (50 mg/kg) significantly decreased SPB from 160.0 ± 5.8 mmHg to 108.8 ± 2.7 mmHg after only four days of administration. In addition, the lower dose of AEAL (10 mg/kg) also normalized the SBP of L-NAME-induced hypertensive rats, however this was only evident after eight days of administration. Conclusion These findings suggest that AEAL affords significant antihypertensive effects against L-NAME-induced hypertensive rats.